Get the Stockscreener App
0.9188
7.18%
-0.0711
After Hours:
.92
0.0012
+0.13%
Lakeshore Biopharma Co Ltd stock is traded at $0.9188, with a volume of 19,167.
It is down -7.18% in the last 24 hours and down -20.80% over the past month.
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
See More
Previous Close:
$0.9899
Open:
$0.965
24h Volume:
19,167
Relative Volume:
0.90
Market Cap:
$19.08M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-8.12%
1M Performance:
-20.80%
6M Performance:
-63.17%
1Y Performance:
-86.71%
1-Day Range:
$0.9188
$0.99
1-Week Range:
$0.87
$1.01
52-Week Range:
$0.87
$8.60
Lakeshore Biopharma Co Ltd Stock (LSB) Company Profile
Name
Lakeshore Biopharma Co Ltd
Sector
Industry
Phone
-
Address
-
Compare LSB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LSB
Lakeshore Biopharma Co Ltd
|
0.9188 | 19.08M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Lakeshore Biopharma Co Ltd Stock (LSB) Latest News
Comparing Fulcrum Therapeutics (NASDAQ:FULC) and Lakeshore Biopharma (NASDAQ:LSB) - Defense World
LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - marketscreener.com
Lakeshore Biopharma Dave Chenn Resigned As Chairman - marketscreener.com
LakeShore Biopharma Announces Leadership Change with New Chairman Appointment - TipRanks
LakeShore Biopharma Enters Financing Lease Agreement for RMB110 Million - TipRanks
LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell) - The Manila Times
Revolutionary Needle-Free Technology Transforms Rabies Vaccine Delivery: China's First Smart Packaging Solution - Stock Titan
TuHURA Biosciences (NASDAQ:HURA) vs. Lakeshore Biopharma (NASDAQ:LSB) Head-To-Head Contrast - Defense World
LakeShore Biopharma Announces Court Dismissal Of Former Chairman's Injunction Applications - MarketScreener
LakeShore Biopharma Adopts Amended Share Incentive Plan - TipRanks
YS Biopharma Shares Surge 18% Pre-Bell on Estimated Preliminary Revenue for Fiscal Year 2023 - Marketscreener.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Revenues Working Against LakeShore Biopharma Co., Ltd's (NASDAQ:LSB) Share Price Following 27% Dive - Simply Wall St
LakeShore Biopharma : Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full Year Guidance Form 6 K - Marketscreener.com
LakeShore Biopharma Posts First Profit Since 2013, Revenue Soars 36% in Strong H1 Earnings - StockTitan
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance - Finansavisen
LakeShore Biopharma provides update on ongoing investigation involving Yi Zhang - TipRanks
LakeShore Biopharma Pursues Criminal Investigation Against Ex-Chairman for Major Corporate Fraud - StockTitan
LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China - GlobeNewswire
Omeros Corp (OMER) Stock Surges Amidst Biotech Sector Activity - GuruFocus.com
LakeShore Biopharma Initiates Biologics License Application - GlobeNewswire
LakeShore Biopharma Co., Ltd Provides Financial Guidance for the Half Year of Fiscal Year of 2025 and Full Year of Fiscal Year 2025 Ending on March 31, 2025 - marketscreener.com
Investors Don't See Light At End Of LakeShore Biopharma Co., Ltd's (NASDAQ:LSB) Tunnel And Push Stock Down 66% - Simply Wall St
LakeShore Biopharma regains Nasdaq compliance - Investing.com
LakeShore Biopharma Advances with Rabies Vaccine Trial - Yahoo Finance
LakeShore Biopharma’s YSJA Rabies Vaccine Heads to Phase III Trial - Contract Pharma
YS Biopharma (YSB) Stock Price, News & Analysis - MarketBeat
LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance - 팜뉴스
LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation - PR Newswire
Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024 - StockTitan
LakeShore changes CEO with new executive appointments - The Pharma Letter
LakeShore Biopharma Announces Leadership Transitions - PR Newswire
YS Biopharma COVID-19 Vaccine Candidate Against Omicron Variant Meets Primary, Secondary Goals - Marketscreener.com
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024 - PR Newswire
LakeShore Biopharma Insider Ups Holding By 3,083% During Year - simplywall.st
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition - PR Newswire
LakeShore Biopharma Co., Ltd (NASDAQ:LSB): When Will It Breakeven? - Yahoo Finance
LSB Stock Price and Chart — NASDAQ:LSB - TradingView
YS Biopharma Co., Ltd. will Change its Ticker to LSB from YS - Marketscreener.com
YS Biopharma Announces Name Change to LakeShore Biopharma - Nasdaq
YS Biopharma Announces Results of Extraordinary General Meeting - PR Newswire
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer - PR Newswire
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - PR Newswire
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine - PR Newswire
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries - PR Newswire
YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024 - PR Newswire
YS Biopharma Announces Appointment of New Directors - PR Newswire
YS Biopharma Announces US$40 Million Private Placement Financing - PR Newswire
YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting - Marketscreener.com
Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target - PR Newswire
YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023 - Marketscreener.com
Lakeshore Biopharma Co Ltd Stock (LSB) Financials Data
There is no financial data for Lakeshore Biopharma Co Ltd (LSB). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.91%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):